ModifiedUnitedHealthcarePolicy CS029ID.B

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Idaho Only)

This policy governs the medical necessity and coverage stance for cytological examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) for breast cancer screening, diagnosis, or as tools to guide surgery for members in Idaho (including Idaho Medicaid Plus).

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Idaho Only)

Policy CodePolicy CS029ID.B

Change TypeRevised clinical evidence and reference sectionsarchived prior version

Effective DateFeb 1, 2026

Next Review Date

Key ActionCheck applicable benefit plan and authorization rules prior to procedures; document prior imaging (mammography, ultrasound/HFUS) when applying this policy.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

3procedures evaluated

Insufficientcoverage stance

38.9%mean inadequate NAF

10-14%NAF sensitivity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDS pooled sensitivity

3,696Zhang et al. sample

Coverage Criteria

Coverage Rationale — Unproven / Not Medically Necessary

Not medically necessary / unproven when used for the following purposes:

Unproven indications: Use of breast ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for (1) breast cancer screening, (2) breast cancer diagnosis, or (3) as alternative tools to guide surgical management

These procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Use of HFUS and FDS

Clinical context on when FDS may be applied:

Preferred evaluation and use of FDS: High-frequency ultrasound (HFUS) is the preferred initial evaluation for pathologic nipple discharge (PND); fiberoptic ductoscopy (FDS) may be considered when HFUS does not establish the cause, location, or extent of the lesion

If HFUS defines the lesion, FDS is unnecessary; combining HFUS with FDS can increase diagnostic accuracy when HFUS is non-diagnostic. Evidence limited by single-center retrospective studies.

Diagnostic accuracy and interpretation

Diagnostic performance considerations from systematic review/meta-analysis:

Interpretation of ductoscopy findings: Ductoscopy using a liberal positive definition (DSany) has high pooled sensitivity (~94%) but low pooled specificity (~47%); using a 'suspicious' threshold (DSsusp) lowers sensitivity (~50%) and increases specificity (~83%).

Heterogeneity in test interpretation and study methods limits reliable discrimination between malignant and benign findings.

NAF/MD cytology and image analysis

NAF and ductal lavage performance notes:

NAF/MD cytology performance: Nipple aspirate fluid (NAF) and mammary ductoscopy (MD) cytology have low sensitivity (10% and 14%, respectively) but were 100% specific in a non-PND cohort; combining NAF and MD cytology and adding image analysis for aneuploidy improved sensitivity up to 55% while maintaining high specificity in the cited small study.

Findings are from a small, uncontrolled study and are limited by sample size and design.

Utility and limitations

Clinical utility and limitations:

Therapeutic potential and limitations of ductoscopy: Ductoscopy may have therapeutic potential (PND resolved in some patients) and can show high specificity and NPV in select series, but is technically challenging with reported unsuccessful procedure rates (up to 30%), procedure-related mild complications (eg, pain, mastitis) and rare major complications; evidence is largely single-center, retrospective, and heterogeneous.

Limitations include high unsuccessful procedure rates, short follow-up, and retrospective designs that limit conclusions about clinical outcomes.

The following procedures are considered unproven and not medically necessary for use in breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgical management due to insufficient evidence of efficacy: breast ductal lavage; breast ductal fluid aspiration and cytology (including nipple aspirate fluid cytology); and fiberoptic ductoscopy, with or without ductal lavage.

The U.S. Food and Drug Administration has stated that nipple aspirate tests are not substitutes for mammograms. Nipple aspirate fluid–based tests should not be used in place of recommended mammography for breast cancer screening or diagnosis.

Ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy are designated not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternatives to guide surgery because available studies show limited diagnostic accuracy, high rates of inadequate samples, and no evidence these interventions improve detection, stage at diagnosis, or mortality.

High-frequency ultrasound (HFUS) is described as the preferred initial evaluation for pathologic nipple discharge (PND). If HFUS can establish the cause, location, and extent of a lesion, further evaluation with fiberoptic ductoscopy (FDS) is unnecessary; FDS may be considered when HFUS is negative or nondiagnostic to increase diagnostic accuracy.

Coding

Applicable CPT Codes (reference only)CPT

19499

Unlisted procedure, breast

Provider Actions and Operational Notes

Prior Authorization

Prior Authorization / Listed Code Guidance

Prior authorization requirements vary by benefit plan. Verify and obtain any required prior authorization before performing procedures related to breast ductal sampling or ductoscopy. Codes commonly associated with procedures in this policy (e.g., unlisted breast procedure CPT 19499) should be submitted with appropriate documentation and prior authorization when the member's plan requires it.

Check the member's federal, state, and contractual benefit terms for prior authorization rules.
Submit clinical documentation supporting medical necessity when prior authorization is requested.

Denial Risk

Denial Risk for Investigational/Unproven Ductal Cytology Procedures

Breast ductal lavage, breast ductal fluid aspiration with cytology, and related ductal cytology procedures are considered unproven or investigational for breast cancer screening and diagnosis due to insufficient evidence of efficacy and are therefore at risk for denial under this policy.

Definitions

inv-20: Ductal lavage (DL)

DefinitionDuctal lavage (DL) is an invasive procedure that removes ductal fluid by inserting a microcatheter into breast ducts via the nipple to obtain cells for cytologic assessment.

Procedure uses describedObtains ductal epithelial cells for cytology as a proposed early indicator of breast cancer; may be combined with ductoscopic visualization or molecular assays.

Limitations notedOnly samples ducts accessed by the catheter; studies report low sensitivity and high rates of inadequate samples; no evidence that DL improves detection, stage at diagnosis, or mortality.

Technical considerationsInvasive and technically challenging; may be uncomfortable and has a steep learning curve limiting widespread use.

inv-21: Nipple aspirate fluid (NAF)

Definition

Eligibility Requirements

There are no top-level eligibility requirement nodes specified in this policy.

Not Covered / Exclusions

Use of ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy for screening, diagnosis, or to guide surgical management is not supported and is considered investigational and not medically necessary.

Per FDA guidance, tests based on nipple aspirate fluid (NAF) should not replace mammography; substituting NAF-based tests for standard imaging may lead to inappropriate management and denial of coverage.

Background

Cytologic examination of breast ductal fluids (obtained via ductal lavage, nipple aspiration/NAF, or fiberoptic ductoscopy) has been investigated as a potential early detection tool, but evidence shows low sensitivity, frequent inadequate or inconclusive samples, and no demonstrated improvement in clinically meaningful outcomes. FDS is technically challenging, examines only a portion of the ductal system, and there is no high-quality evidence that these techniques improve detection rates, earlier stage at diagnosis, or breast cancer mortality.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Idaho Only)

Policy CodePolicy CS029ID.B

Change TypeRevised clinical evidence and reference sectionsarchived prior version

Effective DateFeb 1, 2026

Next Review Date

Key ActionCheck applicable benefit plan and authorization rules prior to procedures; document prior imaging (mammography, ultrasound/HFUS) when applying this policy.

SourceLink

On This Page

Procedures explicitly listed as unproven in this policy include ductal lavage, ductal fluid aspiration with cytology, and fiberoptic ductoscopy (with or without lavage).
Claims for these procedures may be denied as not medically necessary; provide robust documentation if pursued under specific benefit exceptions.

Note

FDA Note — Nipple Aspirate Tests Are Not Substitutes for Mammograms

The U.S. Food and Drug Administration (FDA) has stated that nipple aspirate tests are not substitutes for mammography. Devices for collecting ductal fluid are cataloged under FDA product code KNW, but FDA informational status does not alone establish coverage.

Do not use nipple aspirate tests in place of recommended mammography for screening; coverage may be denied if used as a substitute.

Documentation Required

Reviewer Application — Reference Benefit Plan Terms and Prior Imaging

When applying this policy, reviewers must reference the member's specific benefit plan terms and any applicable federal or state mandates. Reviewers should also document prior imaging and diagnostic attempts (for example, HFUS findings) and whether less invasive, preferred modalities were tried or would have been adequate.

Confirm whether federal, state, or contractual coverage provisions override this Medical Policy.
Document prior imaging (eg, high-frequency ultrasound) and clinical findings that justify escalation to invasive ductal procedures.
When earlier, noninvasive tests have established lesion location/extent (eg, HFUS), invasive ductoscopic procedures may be unnecessary and unsupported by the evidence in this policy.

Step Therapy

Step Therapy / Preferred Use of Less Invasive Modalities

Step therapy or prior trial of less invasive diagnostic modalities may be appropriate before considering invasive ductal procedures. High-frequency ultrasound (HFUS) is preferred for evaluation of pathologic nipple discharge and should be used first when clinically appropriate.

If HFUS adequately identifies the lesion, additional ductoscopy or ductal lavage is generally unnecessary.
For lesions not visualized on HFUS, combining HFUS with FDS may improve diagnostic accuracy but is limited by current evidence; follow benefit plan requirements for step therapy or escalation.
Document trials of HFUS or other noninvasive tests in the medical record when requesting authorization for invasive ductal procedures.

Nipple aspirate fluid (NAF) is fluid obtained noninvasively by nipple aspiration or by fine-needle aspiration for cytologic or molecular analysis.

Diagnostic performanceIn Sauter et al. (2010) NAF cytology sensitivity was low (10%) but specificity was 100% in the non‑PND cohort; combining NAF with MD cytology and image analysis increased sensitivity up to 55% while maintaining 100% specificity in that small study.

Intended roleStudied as a minimally invasive method to detect epithelial abnormalities in ductal fluid as a potential early indicator of breast cancer.

Regulatory cautionFDA states nipple aspirate tests are not substitutes for mammography and should not replace standard imaging for screening or diagnosis.

inv-22: Fiberoptic ductoscopy (FDS)

DefinitionFiberoptic ductoscopy (FDS) is endoscopic intraductal visualization using a very thin endoscope to directly view breast ducts; may be used with aspiration cytology, biopsy, or to guide selective ductectomy.

Clinical uses describedUsed to evaluate pathologic nipple discharge (PND), localize intraductal lesions, and obtain specimens or guide limited intraductal procedures.

Diagnostic accuracy summaryMeta-analysis (Waaijer et al.) found pooled sensitivity of 94% (DSany) but low pooled specificity of 47%; using a 'suspicious' threshold (DSsusp) lowers sensitivity (~50%) and increases specificity (~83%).

LimitationsTechnically challenging, examines only a portion of the ductal system, peripheral lesions may be inaccessible, and available evidence is limited and heterogeneous with no proven outcome benefit.

inv-23: PND (pathologic nipple discharge)

DefinitionPathologic nipple discharge (PND) refers to nipple discharge that is spontaneous, unilateral, and from a single duct or otherwise clinically concerning for an intraductal lesion.

Role of FDS in PNDDuctoscopy detects most underlying malignancies in individuals with PND (pooled sensitivity ~94%) but does not reliably discriminate benign from malignant findings due to low specificity and study heterogeneity.

Alternative evaluationHigh-frequency ultrasound (HFUS) is preferred as initial evaluation for PND; FDS may be considered when HFUS is negative or inconclusive.

inv-24: FDS (alternate entry)

Definition / alternate descriptionFiberoptic ductoscopy (FDS) is an endoscopic intraductal visualization technique that can detect intraductal lesions and may guide selective ductectomy or targeted sampling.

Performance nuancesWhen scoring any visualized ductoscopic finding as positive (DSany) sensitivity is high (~94%) but specificity is low (~47%); applying a 'suspicious' threshold (DSsusp) raises specificity (~83%) but lowers sensitivity (~50%).

Practical limitationsEvidence largely consists of small, single‑center, retrospective studies; interpretation of findings is heterogeneous and may limit applicability.

inv-25: NAF cytology

DefinitionNAF cytology and image analysis refers to cytologic examination of nipple aspirate fluid, often combined with image‑based aneuploidy assessment, to detect epithelial abnormalities.

Reported test performanceSauter et al. reported NAF cytology sensitivity 10% and MD cytology 14% with 100% specificity in the non‑PND cohort; combining cytology with image analysis increased sensitivity to 45%, and a combined model reached 55% sensitivity with 100% specificity in that small study.

Clinical interpretationAlthough specificity can be high in select cohorts, low sensitivity, small sample sizes, and potential false positives (especially with PND) limit reliability for screening or diagnosis.